Table 2.

Direct costs inputs to financial analysis equation.

		Inflammatory Diseases						Chronic Syndromes
Direct Costs Variable Inputs		MS		IBD (UC + CD)		RA		FMS		IBS
			Ref.		Ref.		Ref.		Ref.		Ref.
All direct costs without condition specific treatment (avg.)	b	$16,301	[41]	$7570	[167,168]	$10,060	[169]	$4809	[170]	$4565	[171]
All direct costs with condition specific average treatment (avg.)	i 1	$41,157	[41]	$18,512	[164]	$13,255	[172]	$6239	[20]	$5103	[171]
All direct costs with most cost effective condition specific treatment (avg.)	i 2	$26,397	[41]	$10,191	[173]	$11,038	[174]	$5349	[20]	N/A
All direct costs when treated—Low Severity (avg.)	PL	$31,477	[41,163]	$14,046	[164]	$4430	[165]	$5349	[20]	$490	[175]
All direct costs when treated—High Severity (avg.)	PH	$104,924	[41,163]	$31,060	[164]	$35,695	[165]	$10,269	[20]	$12,999	[175]
Incremental disease progression ‡	ΔP	$73,447	*	$17,014	*	$31,498	*	$4920	*	$11,809	*
Assumed disease progression years †	t	10	†	10	†	10		10	†	10	†
Adverse event probability without condition specific treatment (avg.)	E	75.00%	[41]	60.00%	[164]	2.00%	[176]	0.78%	[177]	N/A
Adverse event cost (avg.)	c	$18,177	[50]	$38,333	[164]	$25,173	[178]	$23,018	[177]	N/A
Adverse event probability with average condition specific treatment (avg.)	e	61.00%	[41]	50.00%	[179]	1.00%	[180]	0.74%	[177]	N/A
Treatment adherence savings (avg.)	a	$6162	[43]	$9792	[164]	$8622	[181]	$1451	[182]	N/A

Abbreviations: “Avg.” = average. * Indicates calculated value; † assumed decade of disease progression; ‡ calculated as cost difference between high and low severity. Literature sources are cited next to each value. N/A = literature source unavailable.